A joint UK-Finland project has revealed why immunotherapy often fails: cancers release a secreted protein called sClever-1, which systematically shuts down T cells. Researchers at the University of Turku and University of Birmingham found high blood levels of sClever-1 may predict resistance to treatment. Crucially, their investigational antibody, bexmarilimab, directly blocks this protein, potentially restoring effectiveness in hard-to-treat cancers. Published in Theranostics, the study could lead to smarter, personalised combination therapies for patients with advanced disease.
Read the full story here.
